Company Overview and News

0
5 Reasons This 12.8% Yielding REIT Could Deliver 420% Total Returns Over The Next Decade

1h seekingalpha
Uniti Group is one of the few high risk stocks I own, thanks to what I consider to be a number of highly attractive characteristics.
BLK UNIT

0
Uniti Group Inc. to Present at the Bank of America Merrill Lynch 2018 Media, Communications & Entertainment Conference

10h globenewswire
LITTLE ROCK, Ark., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that its Executive Vice President, Chief Financial Officer and Treasurer, Mark A. Wallace, and Uniti Towers’ President, Lawrence Gleason, are scheduled to participate at the Bank of America Merrill Lynch 2018 Media, Communications & Entertainment Conference. The presentation is scheduled for 3:15 PM PT / 6:15 PM ET on September 6, 2018 in Beverly Hills, CA.
UNIT

5
Uniti Group: Private Deals

2018-08-11 seekingalpha
The real news was not in the press release; UNIT will likely have a private capital deal by the end of the year.
UNIT WIN CTL

0
Uniti Group Inc. (UNIT) CEO Kenny Gunderman on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Welcome to the Uniti Group Second Quarter 2018 Conference Call. My name is Michelle, and I will be your operator for today. A webcast of this call will be available on the company's website, www.uniti.com, beginning August 9, 2018, and will remain available for 14 days. At this time, all participants are in a listen-only mode. Participants on the call will have the opportunity to ask questions following the company’s prepared comments.
UNIT

0
Pretium Resources (PVG) Q2 Earnings and Revenues Surpass Estimates

2018-08-10 zacks
Pretium Resources (PVG - Free Report) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.
GD PVG UNIT PVG

0
Reading International (RDI) Q2 Earnings Surpass Estimates

2018-08-10 zacks
Reading International (RDI - Free Report) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.29 per share a year ago. These figures are adjusted for non-recurring items.
GD RDIB UNIT RDI

0
Consolidated Water (CWCO) Q2 Earnings Miss Estimates

2018-08-10 zacks
Consolidated Water (CWCO - Free Report) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT

0
Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates

2018-08-10 zacks
Fortress Biotech (FBIO - Free Report) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT FBIO

0
Avid Technology (AVID) Reports Q2 Loss, Tops Revenue Estimates

2018-08-10 zacks
Avid Technology (AVID - Free Report) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.
GD AVID UNIT

0
StoneCastle Financial (BANX) Q2 Earnings Match Estimates

2018-08-10 zacks
StoneCastle Financial (BANX - Free Report) came out with quarterly earnings of $0.40 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT BANX

0
Performant Financial (PFMT) Reports Q2 Loss, Tops Revenue Estimates

2018-08-10 zacks
Performant Financial (PFMT - Free Report) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.
PFMT GD UNIT

0
IntelGenx (IGXT) Reports Q2 Loss, Tops Revenue Estimates

2018-08-10 zacks
IntelGenx (IGXT - Free Report) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT

2
Abeona Therapeutics (ABEO) Reports Q2 Loss, Lags Revenue Estimates

2018-08-10 zacks
Abeona Therapeutics (ABEO - Free Report) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT ABEO ABEOW

0
Taro Pharmaceutical (TARO) Q1 Earnings and Revenues Miss Estimates

2018-08-10 zacks
Taro Pharmaceutical (TARO - Free Report) came out with quarterly earnings of $1.71 per share, missing the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $1.35 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT

0
Uniti Group (UNIT) Q2 FFO and Revenues Lag Estimates

2018-08-10 zacks
Uniti Group (UNIT - Free Report) came out with quarterly funds from operations (FFO) of $0.62 per share, missing the Zacks Consensus Estimate of $0.63 per share. This compares to FFO of $0.60 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT ROX

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 20341J104